GLP-1 receptor agonist medications have changed the way obesity and diabetes are treated, acting on satiety signals and appetite control. However, to better understand the function of GLP-1, it is important to know that their effectiveness does not eliminate the chronic nature of obesity.

It is precisely for this reason that, after discontinuation of therapy, many patients may experience progressive weight regain and the loss of part of the metabolic benefits achieved during treatment.

This is what is referred to as the rebound effect of GLP-1 medications. Understanding why it happens is essential for building more sustainable long-term maintenance strategies.

What is the rebound effect in GLP-1 medication therapy

The rebound effect in GLP-1 receptor agonist therapy refers to the weight regain that may occur after discontinuation of pharmacological treatment. This phenomenon often appears after reaching the peak weight loss achieved during therapy.

Studies report that, within one year of discontinuation, many patients tend to regain a significant portion of the weight lost during treatment. At the same time, the metabolic benefits achieved during the period of drug use may also decline.1 2

The rebound effect is not considered a therapeutic failure, but rather a predictable physiological response linked to the biological mechanisms that regulate appetite, metabolism and the conservation of body energy.3

This is because obesity cannot be interpreted as a temporary condition. Instead, it is a chronic and relapsing disease, in which discontinuation of treatment may favour the reactivation of the processes that contribute to body weight regain.

For this reason, professionals in the field must be fully aware of what happens when GLP-1 therapy is discontinued, since the issue of discontinuation requires particular clinical attention. In fact, there is often not only a return of appetite, but also difficulties in managing long-term metabolic maintenance.

Why weight may return after discontinuing GLP-1 medications

After discontinuation of GLP-1 receptor agonist medications, the body may reactivate certain biological mechanisms that promote weight regain. This process does not depend solely on the return of appetite, but also on a series of metabolic and hormonal adaptations that tend to bring the body back towards its previous energy balance.

Among the main mechanisms involved are the increase in hunger signals, the reduction in energy expenditure and the loss of the drug’s effect on satiety control.4 Added to these elements is what is referred to as the “memory of obesity”, namely the body’s biological tendency to defend its weight set-point even after weight loss.5

The rebound effect therefore reflects the chronic and multifactorial nature of obesity. Once pharmacological therapy is discontinued, the compensatory processes that had been temporarily modulated by treatment may progressively become active again.

Differences between semaglutide, liraglutide and other GLP-1 agonists

The intensity of the rebound effect may also vary depending on the type of GLP-1 agonist used. Molecules with a longer duration of action and more powerful receptor stimulation may lead to more marked counter-regulatory adaptations after discontinuation.

In the case of semaglutide, according to a 2025 study, average weight regain is higher than with liraglutide after discontinuation of therapy. This difference may depend both on the different half-life of the drug and on the greater intensity of its effect on appetite regulation and gastric emptying.6

It should also be considered that the restoration of gastric emptying speed contributes to rebound. During therapy, GLP-1 medications slow gastric transit, promoting a feeling of satiety. After discontinuation, however, this effect tends to decrease rapidly.7

Factors that promote the metabolic rebound effect

The metabolic rebound effect does not depend on a single cause. Among the most relevant elements are the reduction of muscle mass, the slowing of metabolism, the sudden discontinuation of treatment and changes in eating behaviour. Sleep quality and levels of physical activity may also influence the ability to maintain results over the long term.

But let us look in more detail at the possible causes.

Loss of muscle mass and reduction of basal metabolic rate

During weight loss, the body tends to reduce its resting energy expenditure through a process known as adaptive thermogenesis. This metabolic adaptation may persist even after discontinuation of the medication, favouring weight regain.8

Loss of muscle mass represents another important factor. A reduction in muscle tissue may further lower basal metabolic rate, making it more difficult to maintain the weight achieved during therapy.9

For this reason, maintenance strategies often include regular physical activity and greater attention to protein intake, with the aim of preserving both strength and muscle function in patients.

Sudden discontinuation of therapy

Sudden discontinuation of GLP-1 medications may also promote a rapid reactivation of the biological hunger signals.10 With the loss of the drug’s appetite-suppressing effect, satiety control tends to decrease and energy intake may progressively increase.

The slowing of gastric emptying induced by GLP-1 medications also tends to decrease rapidly after discontinuation. This change may contribute to the return of appetite and the reduction of the feeling of fullness experienced during therapy.

In some cases, discontinuation may be linked to the side effects of Ozempic or to economic and treatment continuity issues. For this reason, it is advisable to carefully consider possible gradual treatment discontinuation strategies.11

Sedentary lifestyle and sleep quality

As with any obesity treatment, a sedentary lifestyle may also increase the risk of weight regain after discontinuation. Regular physical activity contributes to the maintenance of lean mass and supports energy metabolism.12

Sleep quality also represents an important factor. Sleeping too little or irregularly may make it more difficult to maintain results over the long term.13

For this reason, rebound prevention strategies tend to include structured interventions focused on movement, physical recovery and daily habits that influence overall metabolic balance.

Emotional aspects and eating behaviour

The rebound effect also involves the psychological and behavioural sphere. After discontinuation of therapy, many people may experience the return of recurring thoughts about food and the constant sensation of hunger, a phenomenon often described as “food noise”.14

This change may influence the relationship with food and make it more difficult to maintain the habits developed during pharmacological treatment. In subjects with eating disorders, the risk of losing control over eating behaviour may become even more significant.

How to prevent the rebound effect with GLP-1

As anticipated, preventing weight regain after discontinuation of GLP-1 medications requires a maintenance strategy built over time. Since obesity is a chronic and relapsing disease, the end of pharmacological therapy does not necessarily coincide with the end of the clinical pathway.

For this reason, rebound management is not based on a single intervention: maintaining results instead requires an integrated approach involving all the relevant areas. These include pharmacotherapy, nutrition, physical activity, metabolic monitoring and behavioural support. Let us briefly examine some of these strategies.

  1. Among the most studied pharmacological strategies are long-term continuation of therapy and gradual dose reduction instead of abrupt discontinuation.
  2. Another central element concerns the maintenance of the lifestyle developed during therapy. Regular physical activity, attention to protein intake and continuity of eating habits may help limit weight regain and support metabolism after discontinuation of treatment.
  3. Likewise, nutritional support, in some clinical pathways, is useful for preserving the quality of weight loss and supporting metabolic balance over the long term.
  4. Alongside clinical monitoring, psychological support is also considered an important element in preventing rebound. Interventions such as motivational interviewing and cognitive behavioural therapy may help patients maintain the habits developed during treatment over time.

In this context, all those strategies aimed at supporting metabolism and body composition may also play a role. For example, the role that supplements for the metabolic system may have within a broader multidisciplinary approach.

References

  1. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252. ↩︎
  2. Aronne LJ; SURMOUNT-4 Investigators. Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply. JAMA. 2024 May 21;331(19):1676. doi: 10.1001/jama.2024.2603. PMID: 38630499. ↩︎
  3. Kolli R, Aoutla S, Jyothi N, et al. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs. Cureus. 2025 Oct 19;17(10):e94926. doi: 10.7759/cureus.94926.  ↩︎
  4. Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes Obes Metab. 2026 Jun;28(6):4546-4558. doi: 10.1111/dom.70713. ↩︎
  5. Avogaro, A., & Fadini, G. P. (2026). Discontinuation of incretin-based therapies in obesity: the complexity of a breakup. European Journal of Internal Medicine, 147, 106833. ↩︎
  6. Tzang C, Wu P, Luo C et al., Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis, eClinicalMedicine, 2025; 90 ↩︎
  7. Tzang C, Wu P, Luo C et al., Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis, eClinicalMedicine, 2025; 90 ↩︎
  8. Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. Diabetes Obes Metab. 2026 Jun;28(6):4546-4558. doi: 10.1111/dom.70713. ↩︎
  9. Lee J et al. Effects of semaglutide on body composition: a systematic review and meta-analysis. Obes Rev 2024; 25(6):e13762. DOI: 10.1111/obr.13762. ↩︎
  10. Avogaro, A., & Fadini, G. P. (2026). Discontinuation of incretin-based therapies in obesity: the complexity of a breakup. European Journal of Internal Medicine, 147, 106833. ↩︎
  11. Avogaro, A., & Fadini, G. P. (2026). Discontinuation of incretin-based therapies in obesity: the complexity of a breakup. European Journal of Internal Medicine, 147, 106833. ↩︎
  12. Bray GA, Bouchard C: The biology of human overfeeding: a systematic review . Obes Rev. 2020, 21:e13040. 10.1111/obr.13040 ↩︎
  13. Jensen SB, Janus C, Lundgren JR, et al.: Exploratory analysis of eating- and physical activity-related
    outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022, 13:4770. 10.1038/s41467-022-32307-y ↩︎
  14. Cook, G. (2026). Quieting “food noise”: How GLP-1s and mindfulness rewire the default mode network (DMN) and reward circuits. Cureus, 18(1), e100818. https://doi.org/10.7759/cureus.100818 ↩︎